GetTopicDetailResponse(id=840298480f, topicName=Infliximab, introduction=Infliximab, content=null, image=null, comments=3, allHits=1344, url=https://h5.medsci.cn/topic?id=9848, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=61984, tagList=[TagDto(tagId=61984, tagName=Infliximab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1443900, encodeId=b1ac14439001f, content=<a href='/topic/show?id=840298480f' target=_blank style='color:#2F92EE;'>#Infliximab#</a>, objectTitle=J Immunother Cancer：英夫利昔單抗((infliximab)和維多珠單抗(vedolizumab)) 治療免疫介導(dǎo)的腹瀉和結(jié)腸炎(IMDC)的療效和安全性, objectType=article, longId=220663, objectId=82c1220663af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c1220663af, replyNumber=0, likeNumber=83, createdTime=2021-11-22, rootId=0, userName=ms4657536712156177, userId=f67c5121442, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c1220663af, moduleTitle=J Immunother Cancer：英夫利昔單抗((infliximab)和維多珠單抗(vedolizumab)) 治療免疫介導(dǎo)的腹瀉和結(jié)腸炎(IMDC)的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=82c1220663af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443899, encodeId=be831443899ce, content=<a href='/topic/show?id=840298480f' target=_blank style='color:#2F92EE;'>#Infliximab#</a>, objectTitle=UEGW 2020：Etrolizumab治療中重度潰瘍性結(jié)腸炎，并不優(yōu)于Infliximab（英夫利昔單抗）, objectType=article, longId=202070, objectId=15bb2020e093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15bb2020e093, replyNumber=0, likeNumber=92, createdTime=2020-10-15, rootId=0, userName=ms4657536712156177, userId=f67c5121442, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15bb2020e093, moduleTitle=UEGW 2020：Etrolizumab治療中重度潰瘍性結(jié)腸炎，并不優(yōu)于Infliximab（英夫利昔單抗）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=15bb2020e093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443898, encodeId=026d14438987a, content=<a href='/topic/show?id=840298480f' target=_blank style='color:#2F92EE;'>#Infliximab#</a>, objectTitle=Eur Arch Otorhinolaryngol：鼓室內(nèi)infliximab給藥是難治性免疫介導(dǎo)性聽力損失的一種安全和有效的挽救療法, objectType=article, longId=183474, objectId=2f341834e435, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f341834e435, replyNumber=0, likeNumber=87, createdTime=2019-11-25, rootId=0, userName=ms4657536712156177, userId=f67c5121442, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f341834e435, moduleTitle=Eur Arch Otorhinolaryngol：鼓室內(nèi)infliximab給藥是難治性免疫介導(dǎo)性聽力損失的一種安全和有效的挽救療法, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2f341834e435)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
